CTC together with Shh and Nrf2 are prospective diagnostic markers for HNSCC.
CTC
Cancer
HNSCC
Nrf2
Shh
Journal
BMC molecular and cell biology
ISSN: 2661-8850
Titre abrégé: BMC Mol Cell Biol
Pays: England
ID NLM: 101741148
Informations de publication
Date de publication:
10 Feb 2024
10 Feb 2024
Historique:
received:
04
12
2023
accepted:
29
01
2024
medline:
10
2
2024
pubmed:
10
2
2024
entrez:
9
2
2024
Statut:
epublish
Résumé
The lack of appropriate prognostic biomarkers remains a significant obstacle in the early detection of Head and Neck Squamous Cell Carcinoma (HNSCC), a cancer type with a high mortality rate. Despite considerable advancements in treatment, the success in diagnosing HNSCC at an early stage still needs to be improved. Nuclear factor erythroid 2-related factor 2 (Nrf2) and Sonic Hedgehog (Shh) are overexpressed in various cancers, including HNSCC, and have recently been proposed as possible therapeutic targets for HNSCC. Circulating Tumor Cell (CTC) is a novel concept used for the early detection of cancers, and studies have suggested that a higher CTC count is associated with the aggressiveness of HNSCC and poor survival rates. Therefore, we aimed to establish molecular markers for the early diagnosis of HNSCC considering Shh/Nrf2 overexpression in the background. In addition, the relation between Shh/Nrf2 and CTCs is still unexplored in HNSCC patients. In the present study, we selected a cohort of 151 HNSCC patients and categorized them as CTC positive or negative based on the presence or absence of CTCs in their peripheral blood. Data on demographic and clinicopathological features with the survival of the patients were analyzed to select the patient cohort to study Shh/Nrf2 expression. Shh and Nrf2 expression was measured by qRT-PCR. Considering significant demographic [smoking, betel leaf (p-value < 0.0001)] and clinicopathological risk factors [RBC count (p < 0.05), Platelet count (p < 0.05), Neutrophil count (p < 0.005), MCV (p < 0.0001), NLR (p < 0.05), MLR (p < 0.05)], patients who tested positive for CTC also exhibited significant overexpression of Shh/Nrf2 in both blood and tissue compared to CTC-negative patients. A strong association exists between CTCs and tumor grade. Following chemotherapy (a combination of Cisplatin, 5FU, and Paclitaxel), the frequency of CTCs was significantly decreased in patients with HNSCC who had tested positive for CTCs. The Kaplan-Meier plot illustrated that a higher number of CTCs is associated with poorer overall survival (OS) in patients with HNSCC. Detecting CTCs, and higher expression of Shh and Nrf2 in HNSCC patients' blood, can be a promising tool for diagnosing and prognosticating HNSCC.
Sections du résumé
BACKGROUND
BACKGROUND
The lack of appropriate prognostic biomarkers remains a significant obstacle in the early detection of Head and Neck Squamous Cell Carcinoma (HNSCC), a cancer type with a high mortality rate. Despite considerable advancements in treatment, the success in diagnosing HNSCC at an early stage still needs to be improved. Nuclear factor erythroid 2-related factor 2 (Nrf2) and Sonic Hedgehog (Shh) are overexpressed in various cancers, including HNSCC, and have recently been proposed as possible therapeutic targets for HNSCC. Circulating Tumor Cell (CTC) is a novel concept used for the early detection of cancers, and studies have suggested that a higher CTC count is associated with the aggressiveness of HNSCC and poor survival rates. Therefore, we aimed to establish molecular markers for the early diagnosis of HNSCC considering Shh/Nrf2 overexpression in the background. In addition, the relation between Shh/Nrf2 and CTCs is still unexplored in HNSCC patients.
METHODS
METHODS
In the present study, we selected a cohort of 151 HNSCC patients and categorized them as CTC positive or negative based on the presence or absence of CTCs in their peripheral blood. Data on demographic and clinicopathological features with the survival of the patients were analyzed to select the patient cohort to study Shh/Nrf2 expression. Shh and Nrf2 expression was measured by qRT-PCR.
RESULTS
RESULTS
Considering significant demographic [smoking, betel leaf (p-value < 0.0001)] and clinicopathological risk factors [RBC count (p < 0.05), Platelet count (p < 0.05), Neutrophil count (p < 0.005), MCV (p < 0.0001), NLR (p < 0.05), MLR (p < 0.05)], patients who tested positive for CTC also exhibited significant overexpression of Shh/Nrf2 in both blood and tissue compared to CTC-negative patients. A strong association exists between CTCs and tumor grade. Following chemotherapy (a combination of Cisplatin, 5FU, and Paclitaxel), the frequency of CTCs was significantly decreased in patients with HNSCC who had tested positive for CTCs. The Kaplan-Meier plot illustrated that a higher number of CTCs is associated with poorer overall survival (OS) in patients with HNSCC.
CONCLUSIONS
CONCLUSIONS
Detecting CTCs, and higher expression of Shh and Nrf2 in HNSCC patients' blood, can be a promising tool for diagnosing and prognosticating HNSCC.
Identifiants
pubmed: 38336617
doi: 10.1186/s12860-024-00500-0
pii: 10.1186/s12860-024-00500-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4Subventions
Organisme : University of Chittagong
ID : 301/2021-22/First Call/25/2022
Informations de copyright
© 2024. The Author(s).
Références
Chow LQ. Head and neck cancer. N Engl J Med. 2020;382(1):60–72.
pubmed: 31893516
doi: 10.1056/NEJMra1715715
Barsouk A, Aluru JS, Rawla P, Saginala K, Barsouk A. Epidemiology, risk factors, and prevention of head and neck squamous cell carcinoma. Med Sci (Basel). 2023;11(2):42.
pubmed: 37367741
Global Cancer Observatory. 2020. https://gco.iarc.fr .
Huang G, Pan ST. ROS-mediated therapeutic strategy in chemo-/radiotherapy of head and neck cancer. Oxid Med Cell Longev. 2020;2020:5047987.
pubmed: 32774675
pmcid: 7396055
doi: 10.1155/2020/5047987
Bottoni P, Scatena R. The role of CA 125 as tumor marker: biochemical and clinical aspects. Adv Exp Med Biol. 2015;867:229–44.
pubmed: 26530369
doi: 10.1007/978-94-017-7215-0_14
Noman AS, Parag RR, Rashid MI, Rahman MZ, Chowdhury AA, Sultana A, et al. Widespread expression of Sonic hedgehog (Shh) and Nrf2 in patients treated with cisplatin predicts outcomes in resected tumors and are potential therapeutic targets for HPV-negative head and neck cancer. Ther Adv Med Oncol. 2020;12:1758835920911229.
pubmed: 32206093
pmcid: 7074584
doi: 10.1177/1758835920911229
Kelly RJ, Ansari AM, Miyashita T, Zahurak M, Lay F, Ahmed AK, et al. Targeting the Hedgehog pathway using itraconazole to prevent progression of Barrett’s esophagus to invasive esophageal adenocarcinoma. Ann Surg. 2021;273(6):e206–13.
pubmed: 31290765
doi: 10.1097/SLA.0000000000003455
Iriana S, Asha K, Repak M, Sharma-Walia N. Hedgehog signaling: implications in cancers and viral infections. Int J Mol Sci. 2021;22(3):1042.
pubmed: 33494284
pmcid: 7864517
doi: 10.3390/ijms22031042
Kumar V, Vashishta M, Kong L, Wu X, Lu JJ, Guha C, Dwarakanath BS. The role of notch, hedgehog, and Wnt signaling pathways in the resistance of tumors to anticancer therapies. Front Cell Dev Biol. 2021;9:650772.
pubmed: 33968932
pmcid: 8100510
doi: 10.3389/fcell.2021.650772
Flemban A, Qualtrough D. The potential role of hedgehog signaling in the luminal/basal phenotype of breast epithelia and breast cancer invasion and metastasis. Cancers. 2015;7(3):1863–84.
pubmed: 26389956
pmcid: 4586799
doi: 10.3390/cancers7030866
Telkoparan-Akillilar P, Panieri E, Cevik D, Suzen S, Saso L. Therapeutic targeting of the NRF2 signaling pathway in cancer. Molecules. 2021;26(5):1417.
pubmed: 33808001
pmcid: 7961421
doi: 10.3390/molecules26051417
Namani A, Matiur Rahaman M, Chen M, Tang X. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer. BMC Cancer. 2018;18(1):46.
pubmed: 29306329
pmcid: 5756380
doi: 10.1186/s12885-017-3907-z
Zhou J, Ding J, Ma X, Zhang M, Huo Z, Yao Y, et al. The Nrf2/KEAP1 pathway modulates nasopharyngeal carcinoma cell radiosensitivity via ROS elimination. Onco Targets Ther. 2020;13:9113–22.
pubmed: 32982300
pmcid: 7494231
doi: 10.2147/OTT.S260169
Lianidou ES, Mavroudis D, Georgoulias V. Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer. Br J Cancer. 2013;108(12):2426–32.
pubmed: 23756869
pmcid: 3694246
doi: 10.1038/bjc.2013.265
Lianidou ES, Strati A, Markou A. Circulating tumor cells as promising novel biomarkers in solid cancers. Crit Rev Clin Lab Sci. 2014;51(3):160–71.
pubmed: 24641350
doi: 10.3109/10408363.2014.896316
Ahmed S, Bharde A, Hossain MM, Parial R, Nayeema NJ, Das M, et al. Circulating tumor cells (CTCs) detection and isolation in different subtypes of early-stage breast cancer patients from Bangladesh. J Clin Oncol. 2023;41(16_suppl):e12529.
doi: 10.1200/JCO.2023.41.16_suppl.e12529
Spector ME, Farlow JL, Haring CT, Brenner JC, Birkeland AC. The potential for liquid biopsies in head and neck cancer. Discov Med. 2018;25(139):251–7.
pubmed: 29906408
pmcid: 6125134
Habli Z, AlChamaa W, Saab R, Kadara H, Khraiche ML. Circulating tumor cell detection technologies and clinical utility: challenges and opportunities. Cancers. 2022;12(7):1930.
doi: 10.3390/cancers12071930
Jethwa AR, Khariwala SS. Tobacco-related carcinogenesis in head and neck cancer. Cancer Metastasis Rev. 2017;36(3):411–23.
pubmed: 28801840
pmcid: 5709040
doi: 10.1007/s10555-017-9689-6
Qayyumi B, Bharde A, Aland G, D’Souza A, Jayant S, Singh N, et al. Circulating tumor cells as a predictor for poor prognostic factors and overall survival in treatment naïve oral squamous cell carcinoma patients. Oral Surg Oral Med Oral Pathol Oral Radiol. 2022;134(1):73–83.
pubmed: 35595620
doi: 10.1016/j.oooo.2022.02.018
Gasparoni LM, Alves FA, Holzhausen M, Pannuti CM, Serpa MS. Periodontitis as a risk factor for head and neck cancer. Med Oral Patol Oral Cir Bucal. 2021;26(4):e430–6.
pubmed: 33340075
doi: 10.4317/medoral.24270
Zolkind P, Lee JJ, Jackson RS, Pipkorn P, Massa ST. Untreated head and neck cancer: Natural history and associated factors. Head Neck. 2021;43(1):89–97.
pubmed: 32914515
doi: 10.1002/hed.26460
Canning M, Guo G, Yu M, Myint C, Groves MW, Byrd JK, et al. Heterogeneity of the head and neck squamous cell carcinoma immune landscape and its impact on immunotherapy. Front Cell Dev Biol. 2019;7:52.
pubmed: 31024913
pmcid: 6465325
doi: 10.3389/fcell.2019.00052
Yu M, Stott S, Toner M, Maheswaran S, Haber DA. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol. 2011;192(3):373–82.
pubmed: 21300848
pmcid: 3101098
doi: 10.1083/jcb.201010021
Plaks V, Koopman CD, Werb Z. Cancer. Circulating tumor cells. Science. 2013;341(6151):1186–8.
pubmed: 24031008
doi: 10.1126/science.1235226
Chalfin HJ, Pramparo T, Mortazavi A, Niglio SA, Schonhoft JD, Jendrisak A, et al. Circulating tumor cell subtypes and T-cell populations as prognostic biomarkers to combination immunotherapy in patients with metastatic genitourinary cancer. Clin Cancer Res. 2021;27(5):1391–8.
pubmed: 33262136
doi: 10.1158/1078-0432.CCR-20-2891
Wu XL, Tu Q, Faure G, Gallet P, Kohler C, Bittencourt MD. Diagnostic and prognostic value of circulating tumor cells in head and neck squamous cell carcinoma: a systematic review and meta-analysis. Sci Rep. 2017;6(1):1–9.
Hernandez BY, Zhu X, Goodman MT, Gatewood R, Mendiola P, Quinata K, et al. Betel nut chewing, oral premalignant lesions, and the oral microbiome. PLoS One. 2017;12(2):e0172196.
pubmed: 28225785
pmcid: 5321455
doi: 10.1371/journal.pone.0172196
Alotaibi M, Valova V, Hänsel T, Stromberger C, Kofla G, Olze H, et al. Impact of smoking on the survival of patients with high-risk HPV-positive HNSCC: A Meta-analysis. In Vivo. 2021;35(2):1017–26.
pubmed: 33622897
pmcid: 8045080
doi: 10.21873/invivo.12345
Su YY, Chien CY, Luo SD, Huang TL, Lin WC, Fang FM, et al. Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil. World J Surg Oncol. 2016;14(1):1–9.
doi: 10.1186/s12957-016-0844-2
Johnson DE, Burtness B, Leemans CR, Lui VW, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6:92.
pubmed: 33243986
pmcid: 7944998
doi: 10.1038/s41572-020-00224-3
Buglione M, Cavagnini R, Di Rosario F, Sottocornola L, Maddalo M, Vassalli L, et al. Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: dental pathologies and osteoradionecrosis (Part 1) literature review and consensus statement. Crit Rev Oncol Hematol. 2016;97:131–42.
pubmed: 26318095
doi: 10.1016/j.critrevonc.2015.08.010
Gröbe A, Blessmann M, Hanken H, Friedrich RE, Schön G, Wikner J, Effenberger KE, Kluwe L, Heiland M, Pantel K, Riethdorf S. Prognostic relevance of circulating tumor cells in blood and disseminated tumor cells in bone marrow of patients with squamous cell carcinoma of the oral cavity. Clin Cancer Res. 2014;20(2):425–33.
pubmed: 24218516
doi: 10.1158/1078-0432.CCR-13-1101
Hsieh JC, Lin HC, Huang CY, Hsu HL, Wu TM, Lee CL, et al. Prognostic value of circulating tumor cells with podoplanin expression in patients with locally advanced or metastatic head and neck squamous cell carcinoma. Head Neck. 2015;37(10):1448–55.
pubmed: 24844673
doi: 10.1002/hed.23779
McMullen KP, Chalmers JJ, Lang JC, Kumar P, Jatana KR. Circulating tumor cells in head and neck cancer: a review. World J Otorhinolaryngology Head Neck Surg. 2016;2(02):109–16.
doi: 10.1016/j.wjorl.2016.05.003
Borsetto D, Polesel J, Tirelli G, Menegaldo A, Baggio V, Gava A, et al. Pretreatment high MCV as an adverse prognostic marker in nonanemic patients with head and neck cancer. Laryngoscope. 2021;131(3):E836–45.
pubmed: 32589769
doi: 10.1002/lary.28882
Szczerba BM, Castro-Giner F, Vetter M, Krol I, Gkountela S, Landin J, et al. Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature. 2019;566:553–7.
pubmed: 30728496
doi: 10.1038/s41586-019-0915-y
Zhang X, Wang Y, Gari A, Qu C, Chen J. Pan-cancer analysis of PARP1 alterations as biomarkers in the prediction of immunotherapeutic effects and the association of its expression levels and immunotherapy signatures. Front Immunol. 2021;12:721030.
pubmed: 34531868
pmcid: 8438309
doi: 10.3389/fimmu.2021.721030
Hayes B, Brady L, Sheill G, Baird AM, Guinan E, Stanfill B, et al. Circulating tumour cell numbers correlate with platelet count and circulating lymphocyte subsets in men with advanced prostate cancer: data from the ExPeCT clinical trial (CTRIAL-IE 15–21). Cancers. 2021;13(18):4690.
pubmed: 34572916
pmcid: 8466183
doi: 10.3390/cancers13184690
Huang SJ, Zhan PF, Chen SB. Mean corpuscular volume as a prognostic factor for patients with habitual alcohol or tobacco use after esophagectomy. Front Oncol. 2021;11:752229.
pubmed: 34868958
pmcid: 8635025
doi: 10.3389/fonc.2021.752229
Wong BW, Stafford ND, Green VL, Greenman J. Prognostic value of the neutrophil-to-lymphocyte ratio in patients with laryngeal squamous cell carcinoma. Head Neck. 2016;38(S1):E1903–8.
pubmed: 26706179
doi: 10.1002/hed.24346
Song Q, Wu JZ, Wang S. Perioperative change in lymphocyte count and prognosis in esophageal squamous cell carcinoma. J Thorac Dis. 2019;11(6):2332.
pubmed: 31372270
pmcid: 6626812
doi: 10.21037/jtd.2019.06.02
Dimitrova V, Arcaro A. Targeting the PI3K/AKT/mTOR signaling pathway in medulloblastoma. Curr Mol Med. 2015;15(1):82–93.
pubmed: 25601471
doi: 10.2174/1566524015666150114115427
Stacy DR, Ely K, Massion PP, Yarbrough WG, Hallahan DE, Sekhar KR, et al. Increased expression of nuclear factor E2 p45-related factor 2 (NRF2) in head and neck squamous cell carcinomas. Head Neck. 2006;28(9):813–8.
pubmed: 16637057
doi: 10.1002/hed.20430
Doheny D, Manore SG, Wong GL, Lo HW. Hedgehog signaling and truncated GLI1 in cancer. Cells. 2020;9(9):2114.
pubmed: 32957513
pmcid: 7565963
doi: 10.3390/cells9092114
Kim H, Heo CM, Oh J, Chung HH, Lee EM, Park J, Lee SH, Lee KH, Lee KT, Lee JK, Cho YK, Park JK. Clinical significance of circulating tumor cells after chemotherapy in unresectable pancreatic ductal adenocarcinoma. Transl Oncol. 2022;16:101321.
pubmed: 34954457
doi: 10.1016/j.tranon.2021.101321